+91-8668442535

Hemophilia Treatment Market By Product (Plasma Derived and Recombinant Coagulation Factor Concentrates, Antifibrinolytic Agents, Desmopressin), By Type (Hemophilia A, Hemophilia B, Others) - Growth, Future Prospects And Competitive Analysis, 2017 - 2025

Hemophilia is a genetic bleeding disorder caused by a deficiency or missing protein needed for clotting, due to which normal blood clotting does not occur. The frequency of bleeding episodes is determined by the severity of hemophilia. There are two main forms of hemophilia, namely hemophilia A and hemophilia B. Hemophilia A is approximately four times more prevalent than hemophilia B.

The incidence of hemophilia A is one in every five thousand live male births. Though studies on the global incidence of hemophilia are scarce, approximately four lakh people are affected. Around 75 percent of people with hemophilia do not receive adequate treatment or have no access to any form of treatment. The major growth drivers for the hemophilia treatment market include a rising diagnosis rate, increased focus on prophylactic treatment, and the development of novel treatments.

The report titled "Hemophilia Treatment Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" offers strategic insights into the overall hemophilia treatment market, along with the market size and estimates for the duration of 2015–2025.

The said research study covers an in-depth analysis of multiple market segments based on the type of product, type of hemophilia, and different geographies. The product types studied for analyzing the overall global hemophilia treatment market are majorly segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, antifibrinolytic agents, and desmopressin. The global hemophilia treatment market is segmented by hemophilia type into hemophilia A, hemophilia B, and others.

The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year. The further cross-sectional analysis presented in terms of product, hemophilia type, and constituent region and country-level markets is also included in this section.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global hemophilia treatment market. Tools such as key player market positioning and an appealing investment proposition provide readers with insights into the global hemophilia treatment market's competitive scenario. This report concludes with a company profiles section that highlights major information about the key players engaged in the global hemophilia treatment market. In-depth competitive environment analysis and historical (2015) market size data are also provided in the report.

Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the hemophilia treatment market. The key players profiled in this report are Baxter International, Inc., Baxalta, Bayer AG, Biogen Idec, Inc., Chugai Pharmaceutical Co., CSL Behring, Genentech, Inc., Hospira, Inc., Ferring B.V., Kedrion, Octapharma AG, Novo Nordisk, Pfizer, Inc., Sanofi SA, Swedish Orphan Biovitrum AB, Shire Plc., and others.

Based on the type of products, the global hemophilia treatment market is segmented as follows:

Plasma-derived coagulation factor concentrates

  • Factor VIII
  • Factor IX
  • Combination

Recombinant Coagulation Factor Concentrates

  • Factor VIII
  • Factor IX
  • Combination
  • Antifibrinolytic Agents
  • Desmopressin

Major contributors to the growth of the hemophilia market include an increase in healthcare expenditure, a preference for prophylactic treatment, an increase in diagnosis rates, and a significant increase in the use of recombinant coagulation factors. In the near future, the recombinant coagulation factor will dominate the global hemophilia market. Recombinant coagulation factors are preferred by most physicians and are thus anticipated to drive the hemophilia market in the given forecast period due to the low risk of bloodborne infection. Plasma-derived coagulation factor is anticipated to have a slow CAGR during the forecast period due to the high risk of blood-associated infections and the limited availability of plasma derived from blood (lack of blood donors).

Based on the type of hemophilia, the global hemophilia treatment market is segmented as follows:

  • Hemophilia A
  • Hemophilia B
  • Others

Hemophilia is the most common blood disorder and is classified into two major types, Hemophilia A and Hemophilia B. Hemophilia A, also called "classic" hemophilia, is the most common type, occurring due to a deficiency of factor VIII. Hemophilia A is four times more prevalent than hemophilia B and thus dominates the global hemophilia treatment market. Rising hemophilia A prevalence and increased on-demand Hemophilia A prophylaxis would boost the global hemophilia market. Hemophilia B, also known as "Christmas disease," occurs due to a factor IX deficiency. Hemophilia C occurs due to a deficiency of factor XI. Acquired hemophilia is the result of medication, illness, or pregnancy. It is rarely observed but can be resolved with proper treatment.

For the purpose of this study, the global hemophilia treatment market is geographically categorized into:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

In 2016, North America dominated the global hemophilia treatment market, followed by Europe. The prevalence of hemophilia is around 134 cases per one million U.S. males. The rising prevalence of hemophilia, increasing healthcare expenditure, awareness about bleeding disorders, extensive research and development in diagnostic technology and treatment, and favorable reimbursement policies are some of the major factors that fuel the growth of the hemophilia treatment market in North America.

Asia Pacific is anticipated to be the fastest-growing market in the forecast period of 2017–2025. An increase in the incidence of hemophilia, raising awareness about the disease, high disposable income, and improved healthcare infrastructure are important factors contributing to the growth of the hemophilia market in the Asia Pacific. In emerging economies such as China and India, there is increasing funding by the government and research institutes for technological advancement in diagnostics and treatment of hemophilia and an increase in the use of recombinant products, thus exhibiting a lucrative opportunity for the Asia-Pacific market.

Frequently Asked Question:

The market for Hemophilia Treatment Market is expected to reach USD$ 15,124.7 Mn in 2025.

The Hemophilia Treatment Market is expected to see significant CAGR growth over the coming years, at 4.5%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Baxter International, Inc., Baxalta, Bayer AG, Biogen Idec, Inc., Chugai Pharmaceutical Co., CSL Behring, Genentech, Inc., Hospira, Inc., Ferring B.V.are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Aug 2017
Category:  Pharmaceuticals
Report ID:   58640
Report Format:   PDF
Pages:   120
Rating:    4.5 (65)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support